

## Special Issue

# Palliative and Precision Medicine Treatment for Biliary Tract Cancers (BTCs)

### Message from the Guest Editor

Biliary tract cancers (BTCs) represent a group of highly heterogeneous malignancies with poor prognosis, posing significant challenges in diagnosis and treatment. With advances in precision medicine, targeted therapies (e.g., against FGFR2 fusions, IDH1 mutations) and immunotherapies have brought new hope for patients with advanced BTC. However, integrating these cutting-edge developments effectively with palliative care to optimize patients' quality of life and prolong survival remains a critical issue in clinical practice. This Special Issue aims to compile the latest research in the field, focusing on the application of precision medicine strategies in personalized BTC treatment and the central role of palliative care throughout disease management. We welcome original research articles, reviews, and clinical case reports that emphasize biomarker-guided targeted therapy, innovations in immunotherapy, symptom management, supportive care, and improvements in patient quality of life.

---

### Guest Editor

Dr. Xiaoyong Huang

Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

---

### Deadline for manuscript submissions

31 July 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/270678](https://mdpi.com/si/270678)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)